IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
IMMUTEP Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Oct 24, 2025
$3.17−0.03 (-0.94%)
Close on Oct 19, 2026
IMMUTEP Ltd income statement
Ratios
Latest available, balances at Jun 30, 2025
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- -594.6%
- Return on equity, FY2025
- -36.9%
Financial strength
- Current ratio
- 11.69
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 528.3%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
Valuation ratios need the share price and fill in once daily prices are connected.